constipation
Conditions
Interventions
The study will be conducted over 8 weeks (60 consecutive days), in which 62 participants will be included, 31 in each group). In the first week, individuals will be drawn and divided in placebo group
Behavioural
Dietary supplement
Sponsors
Faculdade de Medicina de Botucatu - Unesp
Faculdade de Medicina de Botucatu - Unesp
Eligibility
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients with non-dialytic stage V chronic kidney disease; over 18 years of age; who do not have gastroenterological pathologies; do not have cancer; and do not use continuous laxatives
Exclusion criteria
Exclusion criteria: Patients younger than 18 years of age; with gastroenterological pathologies; pregnant women of any gestational age; cancer; patients on continuous use of laxatives; patients with CKD of any other stage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome 1 - Improvement of intestinal habit after supplementation with prebiotics during a period of 60 days; assessed using the criteria of Rome III and the Bristol scale. These parameters are used for the diagnosis of intestinal constipation and in the case of the Bristol scale, it is used to describe the characteristics of the stool, which may help to identify the improvement of the intestinal habit. That is, presence or absence of constipation by means of the criteria of Rome III and score from 1 to 7 by the bristol scale (the categories closest to number 1, characteristic of constipation and when closer to the number 7 characteristic of diarrhea). | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome 2 - Improvement of the lipid profile after 60 consecutive days of prebiotic supplementation; through the evaluation and dosage of total cholesterol and fractions and triglycerides and also by comparing the dosage of medication; ie, reduction of serum levels of total cholesterol and triglycerides without changes in the dosages of medications. ;Outcome 3 -Reduction of inflammation; by reducing serum levels of C-reactive protein; when compared to previous evaluations from study inclusion). | — |
Countries
Brazil
Contacts
Public ContactMarina Berbel Bufarah
Faculdade de Medicina de Botucatu - Unesp
Outcome results
None listed